Fig. 3: Colorectal cancer cell killing effect of the HOPE strategy in vitro.
From: NF-κB-activated oncogene inhibition strategy for cancer gene therapy
Colorectal cells, including CT-26 and HT-29 cells, were transfected with various HOPE plasmids and evaluated at 24, 48, and 72 h post transfection. A Representative fluorescence images of acridine orange/ethidium bromide (AO/EB)-stained CRC cells. Scale bar, 50 μm. B Bar chart showing the numbers of viable colorectal cancer cells after transfection with the HOPE plasmids. CT-26 and HT-29 cells were counted in the fluorescence images of AO/EB-stained cells with ImageJ2 software (n = 3 images). C Proliferation curve of colorectal cancer cells. The proliferation of CT-26 and HT-29 cells was evaluated by the CCK-8 method (n = 3 wells). D Relative mRNA expression of oncogenes. The expression of the TERT, PLK1, MYC, and KRAS genes was measured by qPCR at 48 h post transfection (n = 3 wells). RQ = 2–ΔΔCt; RQ relative quantification. pHOPE-NT/hTERT/hPLK1/hMYC/hKRAS, HOPE plasmids targeting no transcript and the human oncogenes TERT, PLK1, MYC, and KRAS. pHOPE-mTERT/mPLK1/mMYC/mKRAS, HOPE plasmids targeting the mouse oncogenes TERT, PLK1, MYC, and KRAS.
